Adil Abbasi, MD FACP

Learning Objectives

After completing this chapter, the reader should be able to:

• Define septic pulmonary emboli (SPE) and understand their clinical significance.
• Explain the pathophysiology underlying septic pulmonary embolization.
• Identify common and uncommon causes of septic pulmonary emboli.
• Recognize the clinical manifestations associated with septic pulmonary emboli.
• Describe the diagnostic approach, including laboratory and imaging studies.
• Understand current management strategies, including antimicrobial therapy and source control.
• Identify potential complications and their impact on morbidity and mortality.
• Apply evidence-based principles to the evaluation and treatment of patients with suspected septic pulmonary emboli.

Introduction: Septic pulmonary emboli (SPE) are embolic events in which infected thrombi, vegetations, or other septic materials travel through the venous circulation and lodge within the pulmonary arterial vasculature. Unlike bland pulmonary emboli, septic emboli contain microorganisms and inflammatory debris that not only obstruct pulmonary vessels but also introduce infection directly into the pulmonary parenchyma.

Septic pulmonary emboli represent a potentially life-threatening condition requiring prompt recognition and treatment. The condition is most commonly associated with right-sided infective endocarditis, infected intravascular catheters, intravenous drug use, septic thrombophlebitis, and deep soft tissue infections. Delayed diagnosis may result in extensive pulmonary destruction, abscess formation, respiratory failure, septic shock, and death.

The incidence of septic pulmonary emboli has increased with the widespread use of central venous catheters, implantable devices, hemodialysis access, and increasing rates of intravenous substance use disorders. Early diagnosis and source control remain critical determinants of clinical outcomes.

Pathophysiology: The pathogenesis of septic pulmonary emboli begins with the formation of an infected thrombus or vegetation at an extrapulmonary site. Microorganisms invade a thrombus, foreign body, cardiac valve vegetation, or infected vascular structure. Portions of this infected material subsequently detach and enter the venous circulation.

The embolic fragments travel through the superior or inferior vena cava into the right side of the heart and then into the pulmonary arterial circulation. Upon reaching smaller pulmonary vessels, the infected emboli become lodged, producing several simultaneous pathological processes.

Vascular occlusion results in local ischemia and infarction. Simultaneously, microorganisms contained within the embolus invade surrounding lung tissue, causing focal pneumonia, pulmonary abscesses, cavitary lesions, and intense inflammatory responses. Repeated embolization can result in multiple bilateral pulmonary nodules and widespread pulmonary injury.

Commonly isolated pathogens include:

• Staphylococcus aureus, particularly methicillin-resistant Staphylococcus aureus (MRSA)
• Streptococcal species
• Enterococci
• Gram-negative bacilli
• Anaerobic organisms
• Fungal pathogens in immunocompromised patients

The combination of vascular obstruction and active infection distinguishes septic pulmonary emboli from conventional thromboembolic disease.

Causes

Right-Sided Infective Endocarditis: Right-sided infective endocarditis is among the most common causes of septic pulmonary emboli. Infection typically involves the tricuspid valve and is frequently associated with intravenous drug use, intracardiac devices, and indwelling vascular catheters.

Vegetations containing microorganisms detach from infected valves and embolize directly into the pulmonary circulation.

Infected Intravascular Catheters: Central venous catheters, tunneled dialysis catheters, peripherally inserted central catheters (PICCs), and implantable venous access devices may become colonized with microorganisms. Infection can lead to thrombus formation and septic embolization.

Septic Thrombophlebitis: Infection involving peripheral or central veins can result in infected thrombi that subsequently embolize the lungs. Examples include:

• Internal jugular vein thrombosis in Lemierre syndrome
• Pelvic septic thrombophlebitis
• Infected deep vein thrombosis
• Catheter-associated thrombosis

Intravenous Drug Use: Intravenous drug use remains a major risk factor for septic pulmonary emboli. Repeated injections introduce skin flora and contaminants directly into the venous circulation, predisposing patients to bacteremia, right-sided endocarditis, and septic thrombosis.

Skin and Soft Tissue Infections: Severe cellulitis, abscesses, osteomyelitis, diabetic foot infections, and infected wounds may produce septic thrombosis and hematogenous dissemination of infected embolic material.

Cardiac Devices: Infected pacemaker leads, implantable cardioverter-defibrillator leads, and other intracardiac devices can serve as sources of septic embolization.

Other Causes: Less common causes include:

• Suppurative thrombosis associated with malignancy
• Septic abortion
• Postpartum pelvic infections
• Infected vascular grafts
• Septic venous malformations
• Fungal bloodstream infections

Clinical Presentation

Clinical manifestations vary depending on the number of emboli, microbial virulence, underlying host factors, and the presence of associated bacteremia or sepsis.

Fever is the most common presenting symptom and is often accompanied by chills and rigors. Patients frequently experience pleuritic chest pain due to peripheral pulmonary infarction and pleural irritation.

Cough develops in many patients and may be productive or nonproductive. Hemoptysis may occur secondary to pulmonary infarction, cavitary lesions, or pulmonary hemorrhage.

Dyspnea ranges from mild exertional shortness of breath to severe hypoxemic respiratory failure. Tachypnea and hypoxemia are common findings.

Patients with right-sided infective endocarditis may exhibit signs of persistent bacteremia, including fever, malaise, weight loss, and cardiac murmurs.

Physical examination may reveal:

• Fever
• Tachycardia
• Tachypnea
• Hypoxemia
• Crackles
• Pleural friction rub
• Signs of septic shock in severe cases
• Evidence of the primary infectious source

Diagnosis

Laboratory Evaluation: Laboratory studies typically demonstrate evidence of systemic inflammation and infection.

Common findings include leukocytosis, elevated erythrocyte sedimentation rate (ESR), elevated C-reactive protein (CRP), and elevated procalcitonin levels.

Blood cultures are essential and should be obtained before initiating antimicrobial therapy whenever possible. Persistent bacteremia is common and may identify the causative organism.

Additional laboratory testing should include:

• Complete blood count
• Comprehensive metabolic panel
• Coagulation profile
• Lactate level
• Blood cultures from multiple sites

Chest Radiography: Chest radiographs may demonstrate multiple peripheral pulmonary infiltrates, nodules, cavitary lesions, pleural effusions, or wedge-shaped opacities suggestive of pulmonary infarction.

However, chest radiography lacks sensitivity and specificity.

Computed Tomography: Contrast-enhanced chest CT is the imaging modality of choice.

Characteristic findings include:

• Multiple bilateral pulmonary nodules
• Peripheral distribution of lesions
• Cavitary nodules
• Wedge-shaped infiltrates
• Feeding vessel sign
• Pulmonary abscesses
• Pleural effusions

The feeding vessel sign, representing a vessel leading directly to a pulmonary nodule, is highly suggestive of septic embolic disease.

Echocardiography: Echocardiography is essential when infective endocarditis is suspected.

Transthoracic echocardiography may identify large vegetations, whereas transesophageal echocardiography provides greater sensitivity and is often required.

Evaluation for Source Control

A thorough search for the primary infectious source is critical and may include:

• Venous Doppler studies
• CT imaging of suspected infection sites
• Evaluation of vascular access devices
• Dental examination
• Cardiac device assessment

Management: Management requires a combination of antimicrobial therapy, source control, supportive care, and treatment of underlying complications.

Antimicrobial Therapy: Empiric broad-spectrum intravenous antibiotics should be initiated promptly after blood cultures are obtained.

Initial therapy should provide coverage against:

• Staphylococcus aureus including MRSA
• Streptococci
• Gram-negative organisms when clinically indicated

Common empiric regimens include vancomycin combined with an antipseudomonal beta-lactam when healthcare-associated infection is suspected.

Definitive therapy should be tailored according to culture results and susceptibility testing.

Treatment duration typically ranges from four to six weeks but may be longer for infective endocarditis, osteomyelitis, or persistent bacteremia.

Source Control

Successful treatment depends on elimination of the primary source of infection.

Examples include:

• Removal of infected central venous catheters
• Drainage of abscesses
• Surgical debridement of infected tissues
• Extraction of infected cardiac devices
• Treatment of infective endocarditis
• Management of septic thrombophlebitis

Failure to achieve source control is associated with persistent bacteremia and recurrent embolization.

Role of Anticoagulation

The role of anticoagulation remains controversial.

Routine anticoagulation is generally not recommended solely for septic pulmonary emboli because of concerns regarding pulmonary hemorrhage and bleeding from cavitary lesions.

Anticoagulation may be appropriate when there is a separate indication such as:

• Proven deep venous thrombosis
• Mechanical heart valves
• Atrial fibrillation
• Pulmonary embolism unrelated to infection

Clinical decisions should be individualized.

Supportive Care

Supportive measures may include:

• Supplemental oxygen
• Intravenous fluids
• Vasopressors for septic shock
• Mechanical ventilation when indicated
• Intensive care monitoring for critically ill patients

Surgical Intervention

Surgery may be required for patients with:

• Persistent bacteremia despite therapy
• Large right-sided vegetations
• Recurrent embolization
• Severe valve destruction
• Heart failure due to infective endocarditis
• Infected intracardiac devices

Complications

Septic pulmonary emboli may result in significant morbidity and mortality.

Pulmonary abscess formation is among the most common complications and may require prolonged antimicrobial therapy or drainage procedures.

Cavitary lung lesions can lead to pulmonary hemorrhage, persistent infection, and chronic lung damage.

Pleural complications include parapneumonic effusions and empyema.

Respiratory failure may occur due to extensive pulmonary involvement, acute respiratory distress syndrome (ARDS), or overwhelming sepsis.

Persistent bacteremia may lead to metastatic infections involving the brain, bones, joints, kidneys, and soft tissues.

Septic shock remains one of the most serious complications and is associated with high mortality.

Untreated right-sided infective endocarditis can result in progressive valvular destruction, recurrent embolization, and cardiac dysfunction.

Mortality rates vary depending on the underlying source, causative organism, comorbidities, and timing of diagnosis, but remain substantial in patients with severe sepsis or delayed treatment.

Summary

• Septic pulmonary emboli occur when infected thrombi or vegetations embolize to the pulmonary circulation.
• Right-sided infective endocarditis is the most common classic cause.
• Other important causes include infected intravascular catheters, septic thrombophlebitis, intravenous drug use, and deep soft tissue infections.
• Fever, pleuritic chest pain, cough, hemoptysis, and dyspnea are common clinical manifestations.
• Blood cultures and contrast-enhanced chest CT are central to diagnosis.
• Echocardiography is essential when infective endocarditis is suspected.
• Intravenous antimicrobial therapy and aggressive source control are the cornerstones of treatment.
• Routine anticoagulation is generally not indicated unless another clear indication exists.
• Major complications include pulmonary abscesses, cavitary lesions, empyema, respiratory failure, septic shock, and death.
• Early recognition and treatment significantly improve clinical outcomes.

References

Baddour LM, Wilson WR, Bayer AS, et al. (2015). Infective endocarditis in adults: Diagnosis, antimicrobial therapy, and management of complications. Circulation, 132(15), 1435–1486.

Cook RJ, Ashton RW, Aughenbaugh GL, Ryu JH. (2005). Septic pulmonary embolism: Presenting features and clinical course of fourteen patients. Chest, 128(1), 162–166.

Huang RM, Naidich DP, Lubat E, Schinella R, Garay SM, McCauley DI. (1989). Septic pulmonary emboli: CT-radiographic correlation. American Journal of Roentgenology, 153(1), 41–45.

Kuhlman JE, Fishman EK, Teigen C. (1990). Pulmonary septic emboli: Diagnosis with CT. Radiology, 174(1), 211–213.

Konstantinides SV, Meyer G, Becattini C, et al. (2020). ESC Guidelines for the diagnosis and management of acute pulmonary embolism. European Heart Journal, 41(4), 543–603.

Mermel LA, Allon M, Bouza E, et al. (2009). Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection. Clinical Infectious Diseases, 49(1), 1–45.

Ye R, Zhao L, Wang C, Wu X, Yan H. (2014). Clinical characteristics of septic pulmonary embolism in adults: A systematic review. Respiratory Medicine, 108(1), 1–8.

Wilson WR, Gewitz M, Lockhart PB, et al. (2023). Infective endocarditis: Contemporary principles of diagnosis and management. Journal of the American College of Cardiology, 81(15), 1493–1527.